

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2687770

| SUBMISSION TYPE:           | NEW ASSIGNMENT                 |
|----------------------------|--------------------------------|
| NATURE OF CONVEYANCE:      | RELEASE BY SECURED PARTY       |
| CONVEYING PARTY DATA       |                                |
| Name                       | Execution Date                 |
| BANK OF AMERICA, N.A.      | 12/20/2013                     |
| RECEIVING PARTY DATA       |                                |
| Name:                      | SPECTRUM PHARMACEUTICALS, INC. |
| Street Address:            | 11500 S. EASTERN AVE. #240     |
| City:                      | HENDERSON                      |
| State/Country:             | NEVADA                         |
| Postal Code:               | 89052                          |
| PROPERTY NUMBERS Total: 29 |                                |
| Property Type              | Number                         |
| Application Number:        | 12643059                       |
| Application Number:        | 61492583                       |
| Patent Number:             | 7531670                        |
| Patent Number:             | 7588782                        |
| Patent Number:             | 8063323                        |
| Application Number:        | 13246014                       |
| Application Number:        | 13229157                       |
| Patent Number:             | 5447939                        |
| Patent Number:             | 6894071                        |
| Patent Number:             | 6759427                        |
| Patent Number:             | 6303617                        |
| Patent Number:             | 6297226                        |
| Patent Number:             | 6288069                        |
| Patent Number:             | 6630478                        |
| Patent Number:             | 6630490                        |

|                     |          |
|---------------------|----------|
| Patent Number:      | 6982269  |
| Patent Number:      | 6770638  |
| Patent Number:      | 7977369  |
| Application Number: | 12327781 |
| Application Number: | 12809575 |
| Application Number: | 13043333 |
| Application Number: | 13083424 |
| Application Number: | 13083428 |
| Patent Number:      | 8030278  |
| Application Number: | 13220373 |
| Application Number: | 11845648 |
| Patent Number:      | 8026216  |
| Application Number: | 13220358 |
| Application Number: | 13106637 |

#### CORRESPONDENCE DATA

Fax Number: (312)862-2200  
 Phone: 3128622000  
 Email: rob.soneson@kirkland.com  
*Correspondence will be sent via US Mail when the email attempt is unsuccessful.*  
 Correspondent Name: ROB SONESON  
 Address Line 1: 300 N LASALLE  
 Address Line 2: KIRKLAND & ELLIS LLP  
 Address Line 4: CHICAGO, ILLINOIS 60654

|                         |         |
|-------------------------|---------|
| ATTORNEY DOCKET NUMBER: | 11877-9 |
|-------------------------|---------|

|                    |             |
|--------------------|-------------|
| NAME OF SUBMITTER: | ROB SONESON |
|--------------------|-------------|

|            |            |
|------------|------------|
| Signature: | /rsoneson/ |
|------------|------------|

|       |            |
|-------|------------|
| Date: | 01/17/2014 |
|-------|------------|

#### Total Attachments: 6

source=Spectrum Patent Release Reel 029017, Frame 0877#page1.tif  
 source=Spectrum Patent Release Reel 029017, Frame 0877#page2.tif  
 source=Spectrum Patent Release Reel 029017, Frame 0877#page3.tif  
 source=Spectrum Patent Release Reel 029017, Frame 0877#page4.tif  
 source=Spectrum Patent Release Reel 029017, Frame 0877#page5.tif  
 source=Spectrum Patent Release Reel 029017, Frame 0877#page6.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST IN  
UNITED STATES PATENTS**

U.S. Department of Commerce  
U.S. Patent and Trademark Office

THIS TERMINATION AND RELEASE OF SECURITY INTEREST IN U.S. PATENTS (the "***Patent Termination and Release***") dated as of December 20, 2013, from BANK OF AMERICA, N.A., in its capacity as administrative agent (the "***Administrative Agent***") pursuant to a Security and Pledge Agreement (as amended, modified, extended, restated, renewed, replaced, or supplemented from time to time, the "***Agreement***") dated as of September 5, 2012 among Spectrum Pharmaceuticals, Inc., a Delaware corporation (the "***Company***"), Subsidiaries of the Company party thereto (each a "***Grantor***") and collectively with the Company, the "***Grantors***"), and the Administrative Agent. Capitalized terms not defined herein shall have the meanings ascribed to such terms in the Agreement.

WITNESSETH:

WHEREAS, pursuant to the Agreement a continuing security interest and continuing lien (the "***Security Interest***") was granted by the Grantors to the Administrative Agent in and upon certain collateral, including the Specified Patent Collateral (as hereinafter defined) for the ratable benefit of the Secured Parties; and

WHEREAS, a Notice of Grant of Security Interest in Patents was recorded in the Patent Division of the United States Patent and Trademark Office on September 20, 2012 at Reel 029017, Frame 0877;

WHEREAS, the Administrative Agent, on behalf of itself and the Secured Parties, now desires to terminate and release the entirety of its Security Interest in the Specified Patent Collateral;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent, on behalf of itself and the Secured Parties, hereby agrees as follows:

1. Definitions. The term "***Specified Patent Collateral***", as used herein, shall mean all of such Grantor's right, title and interest of every kind and nature as of the date hereof in the patents and patent applications set forth on Schedule I hereto.

2. Release of Security Interest. The Administrative Agent, on behalf of itself and the Secured Parties, hereby (A) terminates, releases and discharges its Security Interest in the Specified Patent Collateral, and (B) reassigns all right, title and interest it may have, if any, in, to or under any Specified Patent Collateral to the applicable Grantor, without representation, warranty or recourse of any kind or nature. The Administrative Agent shall take all further actions, and provide to the Grantors, their successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any

and all documents or other instruments), reasonably requested by the Grantors to more fully and effectively effectuate the purposes of this Patent Termination and Release.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF, the undersigned, on behalf of itself and the Secured Parties, has executed this Patent Termination and Release by its duly authorized officer as of the date first above written.

BANK OF AMERICA, N.A., as Administrative Agent

By: Denise Jones  
Name: Denise Jones  
Title: Assistant Vice President

STATE OF ILLINOIS


COUNTY OF COOK

On this 18 day of December, 2013 before me personally appeared Denise Jones, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

Nancy K. Geleski  
Notary Public

My commission expires: 4/16/17

(SEAL)



**SCHEDULE I**  
**PATENTS AND PATENT APPLICATIONS**

|                                                                                                               |    |            |  |                                   |         |               |         |                                |
|---------------------------------------------------------------------------------------------------------------|----|------------|--|-----------------------------------|---------|---------------|---------|--------------------------------|
| Rare earth metal compounds, methods of making, and methods of using the same                                  | US | 12643059   |  | Dec. 21, 2009<br>(May 23, 2003)   | —       | —             | Pending | Spectrum Pharmaceuticals, Inc. |
| Novel formulation of oxaliplatin with reduced toxicity                                                        | US | 61/492583  |  | Jun. 2, 2011                      | —       | —             | Pending | Spectrum Pharmaceuticals, Inc. |
| Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | US | 11002529   |  | Dec. 1, 2004<br>(Apr. 20, 2001)   | 7531670 | May 12, 2009  | Issued  | Spectrum Pharmaceuticals, Inc. |
| Rare earth metal compositions for treating hyperphosphatemia and related methods                              | US | 11181650   |  | Jul 13, 2005<br>(May 23, 2003)    | 7588782 | Sep. 15, 2009 | Issued  | Spectrum Pharmaceuticals, Inc. |
| Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivative  | US | 12414539   |  | Mar. 30, 2009<br>(Apr. 20, 2001)  | 8063233 | Nov. 22, 2011 | Issued  | Spectrum Pharmaceuticals, Inc. |
| Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivative  | US | 13246014   |  | Sept. 27, 2011<br>(Apr. 20, 2001) | —       | —             | Pending | Spectrum Pharmaceuticals, Inc. |
| Rare earth metal compounds, methods of making, and methods of using the same                                  | US | 13229157   |  | Sep. 9, 2011<br>(May 23, 2003)    | —       | —             | Pending | Spectrum Pharmaceuticals, Inc. |
| Carbon monoxide dependent guanylyl cyclase modifiers and methods of use                                       | US | 08280719   |  | Jul. 25, 1994<br>(Jul. 25, 1994)  | 5447939 | Sept. 5, 1995 | Issued  | Spectrum Pharmaceuticals, Inc. |
| Medical compositions for intravesical treatment of bladder cancer                                             | US | 10285783   |  | Nov. 1, 2002<br>(Nov. 1, 2001)    | 6894071 | May 17, 2005  | Issued  | Spectrum Pharmaceuticals, Inc. |
| Synthesis and methods of use of tetrahydroindolone analogues and derivatives                                  | US | 09/839,289 |  | Apr. 20, 2001<br>(Apr. 20, 2001)  | 6759427 | Jul. 6, 2004  | Issued  | Spectrum Pharmaceuticals, Inc. |
| Novel serotonin-like 9-substituted hypoxanthine and methods of use                                            | US | 09304728   |  | May 4, 1999<br>(May 4, 1998)      | 6303617 | Oct. 16, 2001 | Issued  | Spectrum Pharmaceuticals, Inc. |
| Synthesis and methods of use of 9-substituted guanine derivatives                                             | US | 09419153   |  | Oct. 15, 1999<br>(Oct. 15, 1999)  | 6297226 | Oct. 2, 2001  | Issued  | Spectrum Pharmaceuticals, Inc. |

|    |          |                                  |         |                |         |                                                                                     |
|----|----------|----------------------------------|---------|----------------|---------|-------------------------------------------------------------------------------------|
| US | 09442151 | Nov. 16, 1999<br>(Nov. 16, 1999) | 6288069 | Sept. 11, 2001 | Issued  | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 09899901 | Jul. 6, 2001<br>(Jul. 7, 2000)   | 6630478 | 07-Oct-2003    | Issued  | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 09900844 | Jul. 6, 2001<br>(Jul. 7, 2000)   | 6630490 | 07-Oct-2003    | Issued  | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 10193550 | Jul. 9, 2002<br>(Apr. 20, 2001)  | 6982269 | Jan. 3, 2006   | Issued  | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 10209451 | Jul. 30, 2002<br>(Apr. 20, 2001) | 6770638 | Aug. 3, 2004   | Issued  | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 12053418 | Mar. 21, 2008<br>(Nov. 1, 2001)  | 7977369 | Jul. 12, 2011  | Issued  | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 12327781 | Dec. 3, 2008<br>(Nov. 1, 2001)   | —       | —              | Pending | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 12809575 | Jun. 23, 2011<br>(Dec. 19, 2007) | —       | —              | Pending | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 13043333 | Mar. 8, 2011<br>(Mar. 8, 2010)   | —       | —              | Pending | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 13083424 | Apr. 8, 2011<br>(Nov. 1, 2001)   | —       | —              | Pending | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 13083428 | Apr. 8, 2011<br>(Nov. 1, 2001)   | —       | —              | Pending | Spectrum Pharmaceuticals, Inc.                                                      |
| US | 12390376 | Feb. 20, 2009<br>(Oct. 24, 2002) | 8030278 | Oct. 4, 2011   | Issued  | Spectrum Pharmaceuticals, Inc.;                                                     |
| US | 13220373 | Aug. 29, 2011<br>(Oct. 24, 2002) | —       | —              | Pending | The Board of Trustees of the University of Illinois Spectrum Pharmaceuticals, Inc.; |
| US | 11845648 | Aug. 27, 2007<br>(Oct. 24, 2002) | —       | —              | Pending | Spectrum Pharmaceuticals, Inc.;                                                     |

